Brain metastasis models: What should we aim to achieve better treatments?
BBB
BTB
Brain metastasis
Experimental models
Immunotherapy
Nanomedicines
Organotropism
Preclinical therapy
Small-molecule drugs
Journal
Advanced drug delivery reviews
ISSN: 1872-8294
Titre abrégé: Adv Drug Deliv Rev
Pays: Netherlands
ID NLM: 8710523
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
03
10
2020
revised:
16
11
2020
accepted:
04
12
2020
pubmed:
16
12
2020
medline:
29
9
2021
entrez:
15
12
2020
Statut:
ppublish
Résumé
Brain metastasis is emerging as a unique entity in oncology based on its particular biology and, consequently, the pharmacological approaches that should be considered. We discuss the current state of modelling this specific progression of cancer and how these experimental models have been used to test multiple pharmacologic strategies over the years. In spite of pre-clinical evidences demonstrating brain metastasis vulnerabilities, many clinical trials have excluded patients with brain metastasis. Fortunately, this trend is getting to an end given the increasing importance of secondary brain tumors in the clinic and a better knowledge of the underlying biology. We discuss emerging trends and unsolved issues that will shape how we will study experimental brain metastasis in the years to come.
Identifiants
pubmed: 33321154
pii: S0169-409X(20)30273-8
doi: 10.1016/j.addr.2020.12.002
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-99Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.